Search bioRxiv⌕ Search

Biology subjects

Mullan, M.

Publications and source records attributed to Mullan, M..

2 recordsLinked to original sources

Perturbation-based propagation of bacterial composition uncertainty improves robustness and reproducibility of microbiome differential abundance analysis.

Differential abundance (DA) analysis remains the analytical bottleneck of microbiome science; despite dozens of available methods, results remain poorly reproducible across tools, datasets, and study designs. Three intertwined challenges drive this failure: compositional data structure, stochastic count uncertainty, and complex experimental design; yet no existing method addresses all three simultaneously. Here, we introduce PARALLAX (Perturbation-based Assessment of Robustness Across Latent Logical Axes), a unified DA framework that resolves this gap by propagating compositional uncertainty through per-replicate linear mixed modeling across a structured scale perturbation grid, then summarizes inference through two stability-based metrics: Ppost (effect consistency across Monte Carlo replicates) and Rscale (robustness to scale perturbation). PARALLAX retains uncertainty through the complete inferential pipeline while natively supporting repeated measures and multifactorial designs. Under repeated subsampling, PARALLAX identified fully stable DA taxa in 14.4% of cases, versus 1.7% and 0% for comparators. We applied PARALLAX to two independent longitudinal shotgun metagenomic datasets from mechanistically distinct mouse models: Gulf War toxicant exposure and repetitive head trauma. In both, PARALLAX resolved robust, sex-specific, and time-dependent genus-level shifts while accommodating repeated measures and multifactorial design, tasks that challenged both comparator frameworks. PARALLAX is released as an open-source, AI-compatible R workflow, lowering the barrier to rigorous microbiome DA analysis across complex study designs.

bioinformatics↗

Exploratory analyses suggest less cognitive decline on nilvadipine treatment in very mild Alzheimer’s disease subjects

BackgroundWe explored whether the effects of nilvadipine on cognition were influenced by baseline Alzheimers disease (AD) severity.\n\nMethodsExploratory analyses were performed on the modified intention-to-treat (mITT) dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in very mild, mild and moderate AD subjects. The outcome measures included total and subscale scores of the Alzheimers Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS), an outcome measure recently developed to detect treatment responses in subjects with prodromal AD. Cerebrospinal fluid (CSF) biomarkers A{beta}38, A{beta}40, A{beta}42, total tau and P181 tau were measured in a subset of samples (n = 55). Regression analyses were adjusted for potential confounders and effect modifiers in order to examine the interactive effects of nilvadipine and AD severity on cognitive outcomes over 78-weeks.\n\nResultsCompared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed greater decline on the ADAS-Cog 12. Also in very mild AD, a beneficial effect (as measured by ADCOMS), was detected in the nilvadipine treated group. Therapeutic effects of nilvadipine were also observed for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. CSF A{beta}42/A{beta}40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls.\n\nConclusionThese data suggest that very mild AD subjects benefited from nilvadipine and that future clinical trials of nilvadipine in this population are required to confirm these findings.\n\nTrial RegistrationNCT02017340 Registered 20 December 2013, https://clinicaltrials.gov/ct2/show/NCT02017340\n\nEUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27

clinical trials↗